Translational Diagnostics Core The long-term goal of the Washington University Diabetes Research Center (DRC) Translational Diagnostics Core is to improve human health by supporting clinical laboratory testing services for research in diabetes mellitus and related metabolic disorders. Most Core analyses are performed on samples from human studies and some are performed on samples from animal models. The Core provides expert consultation to investigators so that the most appropriate tests can be chosen while taking cost and number of samples into consideration. In addition to quantification of classic metabolic analytes relevant to diabetes, such as insulin and glucagon, the core also offers assays for diabetes and metabolism relevant molecules, such as adiponectin and TNF?. For some special analytes, the Core maintains contracts with Quest Diagnostics and Mayo Medical Laboratories, so that these analyses can be performed at substantially lower cost to DRC members. Development of new research tests is another important activity of the Translational Diagnostics Core, which makes available to DRC members analyses with enhanced sensitivity and accuracy that incorporate the latest advances in diabetes and metabolism research. The Translational Diagnostics Core provides efficient, high quality diagnostic services promoting the translation of basic scientific discoveries for the prevention, treatment and cure of diabetes and its complications. .
Translational Diagnostics Core The Washington University Diabetes Research Center Translational Diagnostics Core performs efficient clinical laboratory testing to support research in the field of diabetes mellitus. The primary goals of the Core are to reduce the high costs of specialty testing and to provide outstanding quality control so that reliable diabetes- related tests are widely available to investigators focused on the pathogenesis, treatment and cure of diabetes and related metabolic disorders.
| Riek, Amy E; Oh, Jisu; Darwech, Isra et al. (2018) Vitamin D3 supplementation decreases a unique circulating monocyte cholesterol pool in patients with type 2 diabetes. J Steroid Biochem Mol Biol 177:187-192 |
| Musselman, Laura Palanker; Fink, Jill L; Maier, Ezekiel J et al. (2018) Seven-Up Is a Novel Regulator of Insulin Signaling. Genetics 208:1643-1656 |
| Bittel, Adam J; Bohnert, Kathryn L; Reeds, Dominic N et al. (2018) Reduced Muscle Strength in Barth Syndrome May Be Improved by Resistance Exercise Training: A Pilot Study. JIMD Rep : |
| Peterson, Linda R; Xanthakis, Vanessa; Duncan, Meredith S et al. (2018) Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. J Am Heart Assoc 7: |
| Ferguson, Daniel; Blenden, Mitchell; Hutson, Irina et al. (2018) Mouse Embryonic Fibroblasts Protect ob/ob Mice From Obesity and Metabolic Complications. Endocrinology 159:3275-3286 |
| Hampton, Kaia K; Anderson, Katie; Frazier, Hilaree et al. (2018) Insulin Receptor Plasma Membrane Levels Increased by the Progesterone Receptor Membrane Component 1. Mol Pharmacol 94:665-673 |
| Warren, Junco S; Tracy, Christopher M; Miller, Mickey R et al. (2018) Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart. Proc Natl Acad Sci U S A 115:E7871-E7880 |
| Samovski, Dmitri; Dhule, Pallavi; Pietka, Terri et al. (2018) Regulation of Insulin Receptor Pathway and Glucose Metabolism by CD36 Signaling. Diabetes 67:1272-1284 |
| Adams, Melissa T; Gilbert, Jennifer M; Hinojosa Paiz, Jesus et al. (2018) Endocrine cell type sorting and mature architecture in the islets of Langerhans require expression of Roundabout receptors in ? cells. Sci Rep 8:10876 |
| Funk, Steven D; Bayer, Raymond H; Malone, Andrew F et al. (2018) Pathogenicity of a Human Laminin ?2 Mutation Revealed in Models of Alport Syndrome. J Am Soc Nephrol 29:949-960 |
Showing the most recent 10 out of 654 publications
